ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
82,765
-1,03%
Bitcoin
62 948,18
6,47%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Immuneering Corporation (IMRX)

  7. Immuneering Corporation (IMRX) Actualités

IMRX Immuneering Corporation

1,58
0,02 (1,28%)
Après les heures de négociation
Dernière mise à jour : 00:04:32
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Immuneering Corporation IMRX NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,02 1,28% 1,58 00:04:32
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
1,73 1,60 1,73 1,64 1,56
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
09/4/202418:00GLOBEIMM-1-104 is Synergistic with Chemotherapy in Pancreatic..
03/4/202422:05GLOBEImmuneering to Participate in the 23rd Annual Needham..
27/3/202413:00GLOBEImmuneering Announces First Patient Dosed in its Phase 1/2a..
14/3/202412:00GLOBEImmuneering Announces Positive Topline Results from Phase 1..
12/3/202413:00GLOBEImmuneering Appoints Thomas J. Schall, Ph.D. to its Board of..
11/3/202413:00GLOBEImmuneering Doses First Patient in Phase 2a Clinical Trial..
05/3/202423:00GLOBEImmuneering to Present Preclinical Data on Universal-RAS..
04/3/202414:00GLOBEImmuneering to Participate in the Cowen 44th Annual Health..
01/3/202414:05EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
01/3/202414:00GLOBEImmuneering Reports Fourth Quarter and Full Year 2023..
01/3/202413:58EDGAR2Form 8-K - Current report
20/2/202414:00GLOBEImmuneering Receives FDA Fast Track Designation for..
09/2/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202422:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202422:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202422:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202422:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202422:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202422:15EDGAR2Form 8-K - Current report
16/1/202422:37EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
02/1/202422:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/12/202314:00GLOBEImmuneering Announces FDA Clearance of IND Application for..
20/11/202322:05GLOBEImmuneering to Present at the 35th Annual Piper Sandler..
09/11/202322:12EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202322:05GLOBEImmuneering Reports Third Quarter 2023 Financial Results and..
12/10/202322:05GLOBEImmuneering Presents Preclinical Data Demonstrating..
04/10/202322:05GLOBEImmuneering to Present Preclinical Data on IMM-1-104 and..
06/9/202314:00GLOBEImmuneering to Present at the Morgan Stanley Healthcare..
03/8/202322:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/8/202322:05GLOBEImmuneering Reports Second Quarter 2023 Financial Results..
03/8/202322:04EDGAR2Form 8-K - Current report
05/6/202314:00GLOBEImmuneering Completes Dose Escalation in the IMM-1-104 Phase..
30/5/202314:00GLOBEImmuneering to Present at the Jefferies Healthcare..
04/5/202322:05GLOBEImmuneering Reports First Quarter 2023 Financial Results and..

Dernières Valeurs Consultées

NASDAQ
IMRX
Immuneering
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés